	US 12,171,771 B2
	Tryptamine compositions for enhancing neurite outgrowth
Paul Edward Stamets, Shelton, WA (US)
Assigned to TURTLE BEAR HOLDINGS, LLC, Shelton, WA (US)
Filed by TURTLE BEAR HOLDINGS, LLC, Shelton, WA (US)
Filed on Mar. 1, 2023, as Appl. No. 18/115,966.
Application 18/115,966 is a continuation of application No. 16/951,009, filed on Nov. 18, 2020, granted, now 11,660,305.
Claims priority of provisional application 63/007,482, filed on Apr. 9, 2020.
Claims priority of provisional application 62/937,536, filed on Nov. 19, 2019.
Prior Publication US 2023/0210872 A1, Jul. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/661 (2006.01); A61K 9/08 (2006.01); A61K 31/05 (2006.01); A61K 31/352 (2006.01); A61K 31/4045 (2006.01); A61K 31/455 (2006.01); A61K 36/06 (2006.01); A61K 36/066 (2006.01); A61K 36/07 (2006.01); A61K 36/185 (2006.01); A61K 36/73 (2006.01); A61P 25/24 (2006.01)

CPC A61K 31/661 (2013.01) [A61K 9/08 (2013.01); A61K 31/05 (2013.01); A61K 31/352 (2013.01); A61K 31/4045 (2013.01); A61K 31/455 (2013.01); A61K 36/06 (2013.01); A61K 36/066 (2013.01); A61K 36/07 (2013.01); A61K 36/185 (2013.01); A61K 36/73 (2013.01); A61P 25/24 (2018.01)]

6 Claims

1. A method of treating serotonin (5-hydroxytryptamine, 5-HT) receptor disorders, neurological diseases, or augmenting neurogeneration in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising:

0.5-4 mg of norpsilocin or a salt or combinations thereof; and

0.5-4 mg of niacin.